Three industries that are off to a hot M&A start and some takeover candidates.
Idenix shares falls on worries that its Hep C drug may not be competitive against a more potent rival from Gilead Sciences.
The star of Gilead's fourth-quarter call was its Hep C drug GS-7977, helping investor overlook lower-than-expected 2012 guidance.
The market's insatiable demand for Hep C speculative trades was met Tuesday by a little-known Israeli drug maker.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.